Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Lung Cancer

Free Subscription Articles published in Anticancer Res Retrieve available abstracts of 162 articles: HTML format

Single Articles

April 2026
1. DELA CRUZ MC, Yao X, Nealy A, Bailey J, et al
   BIT1 as an Effector of EGFR-TKI-induced Apoptosis via TLE1 Inhibition in Lung Adenocarcinoma Cells.
   Anticancer Res. 2026;46:1799-1818.
   PubMed     Abstract available
   
   
   
2. PRAMUALSIN T, Ei ZZ, Racha S, Sriratanasak N, et al
   Chemosensitizing Effects of Resveratrol Derivatives on p53-dependent Apoptosis Triggered by Cisplatin in Human Lung Cancer Cells.
   Anticancer Res. 2026;46:1893-1901.
   PubMed     Abstract available
   
   
   March 2026
3. SANGSEEKEW W, Boonsombat J, Thongnest S, Sirirak J, et al
   Mechanistic Studies of Anticancer Effects of Salicylaldehyde Benzoylhydrazone in 2D/3D Lung Cancer Cell Cultures.
   Anticancer Res. 2026;46:1365-1387.
   PubMed     Abstract available
   
   
   
4. YU NN, Liu Y, Guo XY, Kim KK, et al
   CD133(+) Lung Cancer Stem-like Cells Resist Plasma-activated Medium Through PRDX5-mediated Antioxidant Defense.
   Anticancer Res. 2026;46:1293-1306.
   PubMed     Abstract available
   
   
   
5. SATOH H, Miyazaki K, Nakamura R, Watanabe A, et al
   Leptomeningeal Metastasis in Patients With EGFR-positive NSCLC: A Propensity-matched Retrospective Study of Patients With EGFR-negative NSCLC.
   Anticancer Res. 2026;46:1685-1695.
   PubMed     Abstract available
   
   
   
6. HAQUE EF, Tanino R, Okimoto T, Hotta T, et al
   Concurrent Pemetrexed With EGFR-TKI Slows the Accumulation of De Novo Mutations During In Vitro Exposure.
   Anticancer Res. 2026;46:1323-1335.
   PubMed     Abstract available
   
   
   February 2026
7. YAMAGUCHI Y, Yoshida T, Higashiyama RI, Masuda K, et al
   Clinical Activity of MET-TKIs in METex14 Skipping NSCLC With Poor Performance Status.
   Anticancer Res. 2026;46:1067-1077.
   PubMed     Abstract available
   
   
   
8. HUNG HY, Lee TH, Chuang CH, Lee MH, et al
   First-Line Afatinib 30 mg Versus 40 mg in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutations: Real-world Efficacy and Tolerability in Taiwan.
   Anticancer Res. 2026;46:917-938.
   PubMed     Abstract available
   
   
   
9. CHECK JH, Check DL, Ganpo-Nkewnkwa N
   Marked Palliative Benefits Seen With Treatment of Very Advanced Breast Cancer With the Progesterone Receptor Modulator Mifepristone.
   Anticancer Res. 2026;46:1153-1165.
   PubMed     Abstract available
   
   
   
10. UCHIYAMA T, Asanuma K, Kita K, Okamoto T, et al
    Amlodipine Suppresses Lung Metastasis by Increasing Cell Stiffness.
    Anticancer Res. 2026;46:689-703.
    PubMed     Abstract available
    
    
    
11. OKADO S, Nakamura S, Sugihara M, Kinoshita F, et al
    Prognostic Factors for Pulmonary Metastasectomy for Colorectal Cancer: A Propensity Score Matching Analysis.
    Anticancer Res. 2026;46:1143-1152.
    PubMed     Abstract available
    
    
    
12. TSUKIOKA T, Nakajima R, Chung K, Okada S, et al
    Tumor Location Significantly Correlates With PD-L1 Status in Patients With Small Sized Non-small Cell Lung Cancer.
    Anticancer Res. 2026;46:911-916.
    PubMed     Abstract available
    
    
    
13. SHEN YW, Lee TH, Hung HY, Liu YW, et al
    Clinicopathologic Predictors of Outcome and Implications for Adjuvant Therapy in Pathologic Stage II Non-small Cell Lung Cancer.
    Anticancer Res. 2026;46:1001-1020.
    PubMed     Abstract available
    
    
    January 2026
14. TAMURA Y, Kawabata S, Yamaguchi R, Asai Y, et al
    TTF-1 Expression and Efficacy of Platinum and Pemetrexed Plus Pembrolizumab in Advanced Lung Adenocarcinoma.
    Anticancer Res. 2026;46:447-456.
    PubMed     Abstract available
    
    
    
15. NORIYAMA K, Todo N, Nakamura S, Tamiya N, et al
    Ginsenoside Rd Improves Anticancer Drug-induced Disturbance in Murine Airway Ciliary Motility.
    Anticancer Res. 2026;46:181-194.
    PubMed     Abstract available
    
    
    
16. KIM HB, Na YS, Kim SH, Lee HJ, et al
    Adenylate Kinase 2 Promotes Tumor Progression in Small-cell Lung Cancer via PI3K/AKT/mTOR Signaling.
    Anticancer Res. 2026;46:205-212.
    PubMed     Abstract available
    
    
    
17. YU E, Oike T, Sakai M, Tashiro M, et al
    Estimation of Tumor Control Probability of Carbon Ion Radiotherapy Using Cancer Type-specific Sensitivity Data.
    Anticancer Res. 2026;46:113-122.
    PubMed     Abstract available
    
    
    
18. UEDA K, Kawaguchi YO, Kataoka Y, Yoden M, et al
    Tumor-associated Neutrophils Promote Lung Cancer Growth and Metastasis via the Neutrophil Elastase.
    Anticancer Res. 2026;46:165-180.
    PubMed     Abstract available
    
    
    
19. SAIJO H, Hirohashi Y, Sumi T, Shijubo N, et al
    Tumor Stroma Infiltrating T Cells Predict the Efficacy of Anti-CTLA-4 Antibody in NSCLC.
    Anticancer Res. 2026;46:301-308.
    PubMed     Abstract available
    
    
    December 2025
20. ASANO Y, Han Q, Li S, Mizuta K, et al
    Selective Synergy of the Combination of Recombinant Methioninase With Cisplatinum and Ivermectin Which Eradicates Lung-Cancer Cells but Has No Synergy and Limited Effect on Normal Fibroblasts.
    Anticancer Res. 2025;45:5389-5398.
    PubMed     Abstract available
    
    
    
21. TAKAHARA Y, Abe R, Nagae S, Tanaka T, et al
    Prognostic Factors in Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
    Anticancer Res. 2025;45:5633-5644.
    PubMed     Abstract available
    
    
    
22. NAGASAKI Y, Yamane H, Takeyama M, Ochi N, et al
    Co-expression of PD1/PD-L1 on Tumor Cells Is Involved in the Regulation of Cell Proliferation.
    Anticancer Res. 2025;45:5341-5350.
    PubMed     Abstract available
    
    
    
23. LEE WY, Tung SL, Chuang SE, Lin SC, et al
    AXL Transcriptionally Up-regulates ISG15 Expression to Mediate Cell Proliferation in Non-small-cell Lung Cancer Cells.
    Anticancer Res. 2025;45:5445-5455.
    PubMed     Abstract available
    
    
    
24. AMANO Y, Tanino R, Sun R, Tsubata Y, et al
    Inhibition of Small-cell Lung Cancer Angiogenesis by Irinotecan Metronomic Chemotherapy and Irinotecan Plus Everolimus.
    Anticancer Res. 2025;45:5287-5297.
    PubMed     Abstract available
    
    
    
25. YASUURA Y, Woo T, Tanaka S, Masuda H, et al
    Impact of Emphysema Severity on Clinicopathological and Molecular Features in Non-small Cell Lung Cancer.
    Anticancer Res. 2025;45:5655-5666.
    PubMed     Abstract available
    
    
    
26. LUO RG, Xie XB, Zhang YY, He YQ, et al
    Ibrutinib Inhibits Tumor Progression, Alleviates Pain, and Protects the Tibia in a Bone Metastasis Model of Lung Cancer.
    Anticancer Res. 2025;45:5477-5490.
    PubMed     Abstract available
    
    
    
27. AHMED F, Khan S
    Potential Role of Tumor-derived MIF in B-Cell Antigen Presentation in Lung Adenocarcinoma: Single-cell and TCGA Analyses.
    Anticancer Res. 2025;45:5369-5387.
    PubMed     Abstract available
    
    
    
28. KREJCI D, Subrt A, Opalka P, Krejci J, et al
    Impact of Baseline Body Mass Index on Immunotherapy Outcomes in Patients With Non-small-cell Lung Cancer.
    Anticancer Res. 2025;45:5579-5586.
    PubMed     Abstract available
    
    
    
29. CHECK JH, Check DL, Wilson C
    Good Quality 66.7% 5-year Overall Survival in Terminal Lung Cancer Patients Treated With Mifepristone.
    Anticancer Res. 2025;45:5785-5798.
    PubMed     Abstract available
    
    
    November 2025
30. KANG JK, Jung JY, Jang WI, Shin YJ, et al
    Comparative Analysis of Dynamic Conformal Arc Therapy and Volumetric-modulated Arc Therapy in Lung Stereotactic Body Radiation Therapy: Evaluating Dosimetric Performance, Treatment Delivery Efficiency, and Plan Robustness.
    Anticancer Res. 2025;45:5121-5138.
    PubMed     Abstract available
    
    
    
31. KIM HM, Kim JY, Lee CG, Song JY, et al
    Nodal Modulator Regulates Chemo- and Radioresistance in Lung Cancer via the Chk2 Pathway.
    Anticancer Res. 2025;45:4817-4826.
    PubMed     Abstract available
    
    
    
32. IWAHASHI Y, Tamiya A, Tanaka T, Tamiya M, et al
    Association Between Administration Timing and Efficacy of Nivolumab in Non-small Cell Lung Cancer Treatment.
    Anticancer Res. 2025;45:5077-5084.
    PubMed     Abstract available
    
    
    
33. SASADA A, Kawachi H, Yamada T, Hata T, et al
    Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression.
    Anticancer Res. 2025;45:5045-5057.
    PubMed     Abstract available
    
    
    
34. LEE CY, Fu YK, Yeh CC, Kuo LK, et al
    Combined Treatment of Cisplatin With Caffeic Acid Phenethyl Ester Demonstrates Additive Growth Inhibition on Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2025;45:4971-4986.
    PubMed     Abstract available
    
    
    October 2025
35. NAKAJIMA Y, Kuribayashi K, Tada A, Nagano A, et al
    Combined Compression and Cooling Therapy for Taxane Chemotherapy-induced Peripheral Neuropathy in Lung Cancer.
    Anticancer Res. 2025;45:4373-4380.
    PubMed     Abstract available
    
    
    
36. OGASAWARA M, Miyashita M, Yamagishi Y, Ota S, et al
    Prognostic Impact of PD-1 Polymorphisms in Non-small Cell Lung Cancer Receiving Dendritic Cell Vaccination.
    Anticancer Res. 2025;45:4295-4304.
    PubMed     Abstract available
    
    
    
37. NAKAO M, Kuriyama M, Hasegawa M, Gomyo R, et al
    Albumin-based Liver Reserve Models as Prognostic Markers for Patients With Extensive-stage Small-cell Lung Cancer.
    Anticancer Res. 2025;45:4483-4491.
    PubMed     Abstract available
    
    
    
38. SEONG H, Kim SH, Kim MH, Eom JS, et al
    Prognostic Impact of ALK Rearrangements in Resected NSCLC: A Systematic Review and Meta-analysis.
    Anticancer Res. 2025;45:4519-4534.
    PubMed     Abstract available
    
    
    September 2025
39. AOKI M, Kamimura GO, Tsuneyoshi Y, Morizono S, et al
    Thorough Lymphadenectomy Impairs Immunotherapy Outcomes for Postoperative Intrathoracic Recurrence of Non-small Cell Lung Cancer.
    Anticancer Res. 2025;45:3971-3981.
    PubMed     Abstract available
    
    
    
40. FUKUI T, Hori S, Hatakeyama Y, Kiriu T, et al
    Stratification by PD-L1 TPS in Advanced NSCLC With Low PD-L1 Expression for Optimizing Immunotherapy.
    Anticancer Res. 2025;45:3859-3875.
    PubMed     Abstract available
    
    
    
41. GLATZEL-PLUCINSKA N, Piotrowska A, Olbromski M, Rzechonek A, et al
    EGFR Levels in NSCLC Are Associated With Expression of SATB1 and EMT-promoting Factors.
    Anticancer Res. 2025;45:3639-3660.
    PubMed     Abstract available
    
    
    
42. HINO H, Maru N, Utsumi T, Matsui H, et al
    Impact of Radiographical Consolidation of Tumor Size of Part-solid Adenocarcinomas on Survival - A Propensity Score-matching Analysis.
    Anticancer Res. 2025;45:3795-3807.
    PubMed     Abstract available
    
    
    August 2025
43. KOH JW, Park SJ
    Down-regulation of SMPDL3B Inhibits the Proliferation, Migration, and Invasion of Lung Adenocarcinoma Cells.
    Anticancer Res. 2025;45:3275-3286.
    PubMed     Abstract available
    
    
    
44. RADES D, Doehring L, Delikanli C, Groh EM, et al
    Estimating the Risk of Radiation Pneumonitis in Elderly Patients With Lung Cancer.
    Anticancer Res. 2025;45:3347-3353.
    PubMed     Abstract available
    
    
    July 2025
45. LI JM, Yang KT, Wu CP
    Physalin F Inhibits Cell Viability and Induces Apoptosis in Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2025;45:3031-3044.
    PubMed     Abstract available
    
    
    
46. SOMBOONVORAVONG W, Petsri K, Racha S, Sriratanasak N, et al
    Artogomezianone Inhibits EGFR and Promotes Apoptosis in Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2025;45:2833-2845.
    PubMed     Abstract available
    
    
    
47. AIDA R, Okano K, Nakata K, Hagiwara H, et al
    Apigenin-induced Apoptosis in Lung Adenocarcinoma A549 Cells: Involvement in IFNA2, TNF, and SPON2 With Different Time Points.
    Anticancer Res. 2025;45:2781-2790.
    PubMed     Abstract available
    
    
    
48. PHANSOM N, Ei ZZ, Innets B, Wattanathana W, et al
    Development of a Benzoxazine-derived Inhibitor Targeting Epithelial-to-Mesenchymal Transition in Lung Cancer.
    Anticancer Res. 2025;45:2807-2815.
    PubMed     Abstract available
    
    
    
49. KIM HL, Park J, Kim HI, Boo M, et al
    Integrating Network Pharmacology and Optimization of Preparation Methods to Enhance the Anticancer Effect of Cordyceps militaris on Lung Cancer.
    Anticancer Res. 2025;45:2963-2984.
    PubMed     Abstract available
    
    
    
50. INNETS B, Racha S, Ei ZZ, Sriratanasak N, et al
    Resveratrol Derivatives Inhibit Pro-survival Akt Signaling Pathway in Lung Cancer.
    Anticancer Res. 2025;45:3021-3029.
    PubMed     Abstract available
    
    
    June 2025
51. OKUNO T, Hongoh M, Tanino R, Okimoto T, et al
    Blood Concentrations of Osimertinib and Its Active Metabolites: Impact on Treatment Efficacy and Safety.
    Anticancer Res. 2025;45:2551-2561.
    PubMed     Abstract available
    
    
    May 2025
52. HWANG HH, Yoo JS, Je JH, Lee HC, et al
    SH003 Inhibits Proliferation and Induces Apoptosis in NSCLC Cell Lines by Inhibiting the Receptor Tyrosine Kinase-related Pathway.
    Anticancer Res. 2025;45:1981-1995.
    PubMed     Abstract available
    
    
    
53. PROBST E, Idel C, Fleckner J, Plotze-Martin K, et al
    Elevated PD-L1 Expression on Circulating Classical Monocytes Upon Checkpoint Inhibitor Therapy Is Associated With Increased Plasma Interleukin 5 in Patients With Lung Cancer.
    Anticancer Res. 2025;45:1915-1925.
    PubMed     Abstract available
    
    
    
54. ASANO Y, Han Q, Mizuta K, Kang BM, et al
    Recombinant Methioninase and Cisplatinum Act Synergistically to Inhibit Lewis Lung Carcinoma Cells But Not Normal Fibroblasts.
    Anticancer Res. 2025;45:1871-1876.
    PubMed     Abstract available
    
    
    
55. DICKE J, Hero L, Kuhl S, Goldbrunner R, et al
    Expression of YAP1 and TAZ in Melanoma-, Bronchial- and Breast Carcinoma Brain Metastasis: Primary vs. Relapsed Tumors.
    Anticancer Res. 2025;45:1807-1812.
    PubMed     Abstract available
    
    
    
56. TSUKAMOTO YO, Ohtsuka T, Yamauchi Y, Mun M, et al
    Efficacy and Prognostic Factors of Surgical Resection for Pulmonary Metastases From Ovarian Cancer.
    Anticancer Res. 2025;45:2071-2078.
    PubMed     Abstract available
    
    
    April 2025
57. AMPIL F, Previgliano C, Heath K, Bozeman A, et al
    Does Aggressive Versus Less Aggressive Non-operative Treatment of Large and Very Large (>/=7 cm) Lung Cancers Matter?
    Anticancer Res. 2025;45:1593-1598.
    PubMed     Abstract available
    
    
    
58. MATSUDA H, Ikeda J, Ogasawara-Nosoko M, Endo M, et al
    Contrasting Role of COMMD5 in Renal Cell Carcinoma: Tumor Suppression and Metastatic Enhancement.
    Anticancer Res. 2025;45:1373-1385.
    PubMed     Abstract available
    
    
    
59. FUTAWATARI N, Fukuyama T, Akimoto Y, Maehara J, et al
    Association Between Kita-kyushu Lung Cancer Antigen-1 Expression in Gastric Cancer and Helicobacter pylori-infection Status.
    Anticancer Res. 2025;45:1599-1606.
    PubMed     Abstract available
    
    
    
60. ZHOU Y, Khawkhiaw K, Thithuan K, Saengboonmee C, et al
    Activation of the gamma-Aminobutyric Acid Receptor Type B Suppresses the Proliferation of Lung Adenocarcinoma Cells.
    Anticancer Res. 2025;45:1513-1523.
    PubMed     Abstract available
    
    
    
61. TANIGUCHI Y, Tamiya A, Kamiyama Y, Sumitani H, et al
    Real-world Data of the Lung Cancer Compact Panel in Non-small Cell Lung Cancer Using Tissue Samples.
    Anticancer Res. 2025;45:1607-1615.
    PubMed     Abstract available
    
    
    March 2025
62. TONE M, Isono T, Yamamoto Y, Takeda Y, et al
    Peripheral CD4(+) T Cells Predict T Cell Immunity in Lung Tissues of Non-small Cell Lung Cancer Patients.
    Anticancer Res. 2025;45:909-920.
    PubMed     Abstract available
    
    
    
63. WATANABE H, Nakamura S, Imamura Y, Okado S, et al
    Impact of Postoperative Therapy on Survival Outcomes in Non-small Cell Lung Cancer Patients With Microscopic Residual Disease.
    Anticancer Res. 2025;45:1193-1204.
    PubMed     Abstract available
    
    
    
64. YUI M, Nakamura S, Koike Y, Hirota K, et al
    Efficacy of Molecular-targeted Agents in Vertebral Metastasis Management in Non-small Cell Lung Cancer.
    Anticancer Res. 2025;45:1105-1115.
    PubMed     Abstract available
    
    
    February 2025
65. MATSUKIDA A, Imai H, Shiono A, Ryuno Y, et al
    Efficacy and Safety of Amrubicin Monotherapy After Chemoradiotherapy in Patients With Relapsed Limited Disease Small-cell Lung Cancer.
    Anticancer Res. 2025;45:733-741.
    PubMed     Abstract available
    
    
    
66. TAN XT, Huang SW, Lin YC, Lin FY, et al
    A New PD-L1 Nanobody Enhances Cell Death in Lung Cancer In Vitro and In Vivo.
    Anticancer Res. 2025;45:535-547.
    PubMed     Abstract available
    
    
    
67. KOH YW, Han JH, Haam S, Lee HW, et al
    Immunosuppressive State May Lead to Brain Metastases in Lung Squamous Cell Carcinoma: Gene Expression and Immunohistochemical Analysis.
    Anticancer Res. 2025;45:525-534.
    PubMed     Abstract available
    
    
    
68. MOTOYAMA M, Shigefuku R, Tanaka N, Nishizawa M, et al
    Acyclic Retinoid Inhibits the EGFR/AKT Signaling Pathway and Cancels Cisplatin-resistant Cell Characteristics.
    Anticancer Res. 2025;45:433-443.
    PubMed     Abstract available
    
    
    January 2025
69. KAWAMURA H, Imaizumi T, Miyakawa T, Nakao E, et al
    Development of a Prognostic Model for Stage IV Colorectal Cancer Using Metastatic Patterns.
    Anticancer Res. 2025;45:341-350.
    PubMed     Abstract available
    
    
    
70. IMPROTA G, Vita G, Tartarone A, Calice G, et al
    EGFR Exon 19 Insertions: Do Patients Respond to Tyrosine Kinase Inhibitor Treatment?
    Anticancer Res. 2025;45:335-340.
    PubMed     Abstract available
    
    
    
71. YOSHIDA K, Watanabe K, Nishimura T, Ikushima H, et al
    Improvement in Survival in Patients With Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2025;45:295-305.
    PubMed     Abstract available
    
    
    
72. LEE JY, Kim JN, Cho SG
    Kisspeptin Retards Tumor Growth of Lewis Lung Carcinoma Cells Through p38 MAPK-mediated Senescence.
    Anticancer Res. 2025;45:113-122.
    PubMed     Abstract available
    
    
    
73. YAMAUCHI K, Komuta R, Tanabe H, Yokoyama M, et al
    Real-world Outcomes of Durvalumab Consolidation in Elderly Patients With Unresectable NSCLC Following CCRT With Daily Low-dose Carboplatin.
    Anticancer Res. 2025;45:369-378.
    PubMed     Abstract available
    
    
    December 2024
74. TSURUOKA K, Tamura Y, Shimazu Y, Arai M, et al
    Association Between PD-L1 Expression and Efficacy of Chemoimmunotherapy in Extensive-stage Small Cell Lung Cancer.
    Anticancer Res. 2024;44:5531-5539.
    PubMed     Abstract available
    
    
    
75. FUJIWARA M, Mimae T, Kushitani K, Tsubokawa N, et al
    Mitochondrial Metabolism as a Potential Novel Therapeutic Target for Lung Adenocarcinoma.
    Anticancer Res. 2024;44:5241-5252.
    PubMed     Abstract available
    
    
    
76. TANIGUCHI Y, Shigenobu T, Hayashi A, Hirahara A, et al
    Optimal Therapy for Postoperative Recurrence: Does Salvage Radiation Work for Locoregional Recurrence?
    Anticancer Res. 2024;44:5541-5549.
    PubMed     Abstract available
    
    
    
77. WEI L, Jiang Z, Chen S, Xia N, et al
    Pseudogene KRT17P3 Promotes NSCLC Progression Through Mir-338-3p/USP7/C-Myc.
    Anticancer Res. 2024;44:5405-5423.
    PubMed     Abstract available
    
    
    
78. DE MORAES FCA, Souza MEC, DA Silva ER, Kreuz M, et al
    Impact of ABCG2 rs2231142(421C>A) Variant on the Clinical Outcomes of Patients With EGFR-mutated Non-small Cell Lung Cancer Treated With Gefitinib: A Comprehensive Meta-analysis.
    Anticancer Res. 2024;44:5361-5370.
    PubMed     Abstract available
    
    
    
79. HAYASHI A, Kamio K, Miyanaga A, Yoshida K, et al
    Ivermectin Enhances Paclitaxel Efficacy by Overcoming Resistance Through Modulation of ABCB1 in Non-small Cell Lung Cancer.
    Anticancer Res. 2024;44:5271-5282.
    PubMed     Abstract available
    
    
    
80. CANON V, Lopez-Guerra JL, Arteagoitia A, Del Hoyo O, et al
    Impact of Radiation Dose on the Survival of Patients With Non-small Cell Lung Cancer Treated With Palliative Intent: Results of a Multicenter Prospective Study.
    Anticancer Res. 2024;44:5477-5484.
    PubMed     Abstract available
    
    
    
81. TEGENBOSCH C, Vekens K
    Recurrence Risk and Its Impact on Current Treatment Strategies in Early and Locally Advanced NSCLC.
    Anticancer Res. 2024;44:5495-5500.
    PubMed     Abstract available
    
    
    November 2024
82. SHOJI F, Minemura A, Kozuma Y, Nouno T, et al
    A Prospective Observational Study Analyzing the Diversity and Specific Composition of the Oral and Gut Microbiota in Lung Cancer Patients.
    Anticancer Res. 2024;44:5067-5080.
    PubMed     Abstract available
    
    
    
83. NASER S, Schulz M, Schuchart S, VON Hammerstein-Equord A, et al
    Metabolomic Profiling of Large Extracellular Vesicles in Patients Suffering from Small Cell Lung Cancer.
    Anticancer Res. 2024;44:4729-4735.
    PubMed     Abstract available
    
    
    
84. NAKASHIMA K, Umeda Y, Demura Y, Yamaoka K, et al
    Long-term Responders to Nanoparticle Albumin-bound Paclitaxel Following Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer.
    Anticancer Res. 2024;44:5105-5111.
    PubMed     Abstract available
    
    
    
85. VEHLOW A, Lange I, Lagies S, Kammerer B, et al
    Cytotoxic and Radiosensitizing Effects of European and African Propolis in 3D Lung Carcinoma Cell Cultures.
    Anticancer Res. 2024;44:4801-4811.
    PubMed     Abstract available
    
    
    
86. KUO LK, Fu YK, Yeh CC, Lee CY, et al
    Combined Treatment of Caffeic Acid Phenethyl Ester With Docetaxel Inhibits Survival of Non-small-cell Lung Cancer Cells via Suppression of c-MYC.
    Anticancer Res. 2024;44:4915-4928.
    PubMed     Abstract available
    
    
    
87. SUNG KS, Han SJ, Lee J, Kwon M, et al
    Identification of Plasma Protein Biomarkers for Predicting Lung Cancer.
    Anticancer Res. 2024;44:5147-5155.
    PubMed     Abstract available
    
    
    
88. JEON M, Yoo S, Park S, Choi Y, et al
    Over-expression of Transmembrane Protein 158 Predicts Aggressive Tumor Behavior and Poor Prognosis in Lung Cancer.
    Anticancer Res. 2024;44:4885-4893.
    PubMed     Abstract available
    
    
    
89. NGUYEN TQ, Nguyen DH, Phan UTT, Tran PTT, et al
    Fenbendazole and Diisopropylamine Dichloroacetate Exert Synergistic Anti-cancer Effects by Inducing Apoptosis and Arresting the Cell Cycle in A549 Lung Cancer Cells.
    Anticancer Res. 2024;44:4761-4772.
    PubMed     Abstract available
    
    
    
90. SUZUKI Y, Maeno K, Kagawa Y, Sone K, et al
    Association of Plasma Nestin With Response to Immune Checkpoint Inhibitors Combined With Chemotherapy in Extensive-stage Small-cell Lung Cancer: A Pilot Study.
    Anticancer Res. 2024;44:5095-5104.
    PubMed     Abstract available
    
    
    October 2024
91. NATHANI A, Khan I, Tanimoto MH, Mejia JAA, et al
    Antitumor Potential of Guttiferone E Combined With Carboplatin Against Osimertinib-resistant H1975 Lung Cancer Through Apoptosis.
    Anticancer Res. 2024;44:4175-4188.
    PubMed     Abstract available
    
    
    
92. TSUKAGUCHI A, Tamiya A, Fukuda S, Iwahashi Y, et al
    Safety and Efficacy of Durvalumab After Chemoradiotherapy in Antinuclear Antibody-positive Patients With Non-small Cell Lung Cancer.
    Anticancer Res. 2024;44:4517-4524.
    PubMed     Abstract available
    
    
    
93. ASANO Y, Yamamoto N, Hayashi K, Takeuchi A, et al
    Serum Inflammatory Dynamics as Novel Biomarkers for Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer With Bone Metastases.
    Anticancer Res. 2024;44:4493-4503.
    PubMed     Abstract available
    
    
    
94. KIM HJ, Kim DY
    Potential Anti-tumor Properties of PDIA4 in Lung Adenocarcinoma.
    Anticancer Res. 2024;44:4309-4315.
    PubMed     Abstract available
    
    
    
95. CHOI YJ, Ramos SC, Sim HB, Han JY, et al
    Promising Approach for Optimizing In Vivo Fluorescence Imaging in a Tumor Mouse Model: Precision in Cancer Research.
    Anticancer Res. 2024;44:4347-4358.
    PubMed     Abstract available
    
    
    
96. KURIBAYASHI K, Hirano J
    True Benefits of Immune Checkpoint Inhibitors in the Treatment of Malignant Pleural Mesothelioma in Japan.
    Anticancer Res. 2024;44:4135-4145.
    PubMed     Abstract available
    
    
    
97. KWON M, Lim D, Park J, Gil W, et al
    MiR-140-3p Improves Sensitivity to Docetaxel by Suppressing PD-L1/ABCG2/MVP Expression in Lung Adenocarcinoma.
    Anticancer Res. 2024;44:4283-4299.
    PubMed     Abstract available
    
    
    
98. LIN PJ, Kuo YC, Hu PW, Chen WL, et al
    Magnolol Induces Apoptosis and Suppresses Immune Evasion in Non-small Cell Lung Cancer Xenograft Models.
    Anticancer Res. 2024;44:4327-4337.
    PubMed     Abstract available
    
    
    
99. KIM I, Choi SH, Lee SY, Yoo SS, et al
    PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC.
    Anticancer Res. 2024;44:4505-4516.
    PubMed     Abstract available
    
    
    September 2024
100. SONG HJ, Sharma S, Kim T, Kim YH, et al
     Macrophage-induced Expression of TonEBP/NFAT5 Is Associated With Gefitinib Resistance and Migration in PC-9 Cells.
     Anticancer Res. 2024;44:3867-3874.
     PubMed     Abstract available
     
     
     
101. CHEN HJ, Cheng WC, Chen CH, Tu CY, et al
     Efficacy of Respiration-controlled Radiotherapy Among Patients With Locally Advanced-stage Lung Cancer: A Population-based Study.
     Anticancer Res. 2024;44:4093-4100.
     PubMed     Abstract available
     
     
     
102. SAGIE N, Romanov E, Kezerle Y, Meirovitz A, et al
     Expression Analysis of SSTR 1, 2 and 3 in Small-cell Lung Cancer Patients as Targets for Future Peptide Receptor Radionuclide Therapy.
     Anticancer Res. 2024;44:3807-3812.
     PubMed     Abstract available
     
     
     
103. TAKEDA K, Kikuchi Y, Sawada YU, Kumamoto T, et al
     Simultaneously Detected Liver and Lung Metastases from Colorectal Carcinoma: A Potential Treatment Strategy.
     Anticancer Res. 2024;44:3945-3954.
     PubMed     Abstract available
     
     
     
104. HAYASHI K, Ishikawa H, Fujiwara K, Nakai M, et al
     Stereotactic Ablative Radiotherapy for Early-stage Lung Cancer in Patients With Left Ventricular Assist Device: A Case Series.
     Anticancer Res. 2024;44:4113-4117.
     PubMed     Abstract available
     
     
     August 2024
105. URAMOTO H, Motono N, Iijima Y, Nakajima Y, et al
     Long-term Outcomes of Salvage Surgery Versus Induction Therapy Followed by Surgical Resection for Advanced NSCLC: A Propensity Score-matched Analysis.
     Anticancer Res. 2024;44:3525-3531.
     PubMed     Abstract available
     
     
     
106. ARICO D, Macri P, Bambaci M, Leone G, et al
     Non-palpable Pulmonary Nodules and Uniportal-VATS: Radio-guided Localization (ROLL) Experience of a Lung Multidisciplinary Team.
     Anticancer Res. 2024;44:3507-3514.
     PubMed     Abstract available
     
     
     
107. IMAMURA Y, Kato T, Nomata Y, Okado S, et al
     Efficacy of Immune Checkpoint Inhibitors in Postoperative Recurrence of Wild-type EGFR Non-Small Cell Lung Cancer.
     Anticancer Res. 2024;44:3451-3461.
     PubMed     Abstract available
     
     
     
108. NOHIRA S, Kuramitsu S, Ohno M, Fujita M, et al
     Tertiary Lymphoid Structures in Brain Metastases of Lung Cancer: Prognostic Significance and Correlation With Clinical Outcomes.
     Anticancer Res. 2024;44:3615-3621.
     PubMed     Abstract available
     
     
     July 2024
109. OHGURI T, Morisaki T, Itamura H, Tani S, et al
     Prophylactic Effect of Clarithromycin on Radiation Pneumonitis in IMRT for Lung Cancer.
     Anticancer Res. 2024;44:2989-2995.
     PubMed     Abstract available
     
     
     
110. LUUKKAINEN MEK, Koivunen JP
     ALK Inhibitor and Chemotherapy Combinations in Models of ALK-Translocated NSCLC.
     Anticancer Res. 2024;44:2805-2813.
     PubMed     Abstract available
     
     
     
111. ZO S, Kim C, Lee HY, Park G, et al
     Comparative Analysis of Clinical Characteristics and Prognosis Between Primary Lung Cancers Identified as Screening Detected and Incidentally Detected Pulmonary Nodules.
     Anticancer Res. 2024;44:3163-3173.
     PubMed     Abstract available
     
     
     
112. IGATA F, Inoue H, Ikeda T, Nakao A, et al
     Comparison of Real-world Efficacy and Safety of Atezolizumab and Durvalumab in Combination With Chemotherapy for First-line Treatment of Extensive-stage Small-cell Lung Cancer.
     Anticancer Res. 2024;44:3175-3183.
     PubMed     Abstract available
     
     
     
113. EBI N, Inoue H, Igata F, Okuma R, et al
     Clinical Association Between Immune-related Adverse Events and Treatment Efficacy in Patients With Non-small-cell Lung Cancer Treated With Nivolumab-Ipilimumab-based Therapy.
     Anticancer Res. 2024;44:3087-3095.
     PubMed     Abstract available
     
     
     June 2024
114. SWITLIK W, Wyzewski Z, Gregorczyk-Zboroch K, Gietler M, et al
     Deciphering the Role of miR-30a-5p and DLGAP1 Gene in Non-small Cell Lung Cancer.
     Anticancer Res. 2024;44:2445-2451.
     PubMed     Abstract available
     
     
     
115. ANO S, Kikuchi N, Okauchi S, Numata T, et al
     Real Clinical Practice of Combined Atezolizumab Plus Chemotherapy in Patients With Small Cell Lung Cancer.
     Anticancer Res. 2024;44:2725-2730.
     PubMed     Abstract available
     
     
     
116. ENDO K, Tanaka H, Matsuo H, Onoda T, et al
     Adverse Event Profile of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel Combination Therapy Based on JADER.
     Anticancer Res. 2024;44:2653-2660.
     PubMed     Abstract available
     
     
     
117. SEO HR, Kim HJ, Ryu H, Song JY, et al
     Ionizing Radiation-treated NRF2-deficient Cancer Cells Promote Type I Interferon Signaling in Immune Cells.
     Anticancer Res. 2024;44:2577-2585.
     PubMed     Abstract available
     
     
     
118. PARK JS, Park HY, Choi Y
     Effect of Epidermal Growth Factor Receptor Mutation on Positron Emission Tomography/Computed Tomography in Lung Cancer.
     Anticancer Res. 2024;44:2681-2687.
     PubMed     Abstract available
     
     
     May 2024
119. SOLIS-ESTRADA J, Arredondo-Espinoza E, Pioquinto-Avila E, Gonzalez-Cruz AO, et al
     Design and Evaluation of a Humanized Anti-EGFR huscFv Antibody Fragment in Combination With Metformin in A549 Cells In Vitro.
     Anticancer Res. 2024;44:1955-1962.
     PubMed     Abstract available
     
     
     
120. CHEN LH, Tsai YF, Wu WT, Chiu KL, et al
     Association of Matrix Metalloproteinase-9 Genotypes With Lung Cancer Risk in Taiwan.
     Anticancer Res. 2024;44:1845-1852.
     PubMed     Abstract available
     
     
     
121. RADES D, Cremers F, Janssen S, Bartscht T, et al
     Associations Between Mean Lung Dose and Prevalence of Radiation Pneumonitis in Elderly Lung Cancer Patients.
     Anticancer Res. 2024;44:2073-2079.
     PubMed     Abstract available
     
     
     
122. CHOI YJ, Chung YH, Lee K, Jeong M, et al
     SH003 Enhances the Anti-cancer Effects of Dabrafenib on Lung Cancer Harboring BRAF G469A Mutation by Inhibiting the MAPK Signaling Pathway.
     Anticancer Res. 2024;44:1905-1913.
     PubMed     Abstract available
     
     
     
123. JI N, Lee Y, Lee SH, Kim HS, et al
     Diagnostic Value of Immunostaining for Thyroid Transcription Factor 1 (TTF1) and Paired Box 8 (PAX8) in Distinguishing Pulmonary Metastases of Mesonephric and Mesonephric-like Adenocarcinomas from Primary Lung Adenocarcinomas.
     Anticancer Res. 2024;44:2159-2170.
     PubMed     Abstract available
     
     
     
124. CHARPIDOU A, Mani M, Kokkotou E, Stournara L, et al
     Molecular Diagnostics and Treatment Patterns in Metastatic Non-small Cell Lung Cancer Patients: Real World Evidence from Greece: LACHESIS Study.
     Anticancer Res. 2024;44:2063-2072.
     PubMed     Abstract available
     
     
     
125. KOH YW, Han JH, Haam S, Lee HW, et al
     Prediction of Responsiveness to PD-L1/PD-1 Inhibitors Using miRNA Profiles Associated With PD-L1 Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma.
     Anticancer Res. 2024;44:2081-2089.
     PubMed     Abstract available
     
     
     April 2024
126. MAEZAWA Y, Taguchi M, Kawakami T, Inui T, et al
     Patient Age and EGFR-positive Non-small Cell Lung Cancer: A Multicenter Retrospective Study.
     Anticancer Res. 2024;44:1751-1757.
     PubMed     Abstract available
     
     
     
127. CHIU KL, Wang SC, Li CH, Shen TC, et al
     The Contribution of Double-strand Break Repair Radiation Sensitive Protein 51 Genotypes to Lung Cancer in Taiwan.
     Anticancer Res. 2024;44:1409-1416.
     PubMed     Abstract available
     
     
     
128. HASHIMOTO K, Kaira K, Imai H, Miura YU, et al
     Metabolic Tumor Volume as Significant Predictor for Chemotherapy Containing PD-L1 Blocker in Extensive Stage Small Cell Lung Cancer.
     Anticancer Res. 2024;44:1541-1551.
     PubMed     Abstract available
     
     
     March 2024
129. INOMATA M, Minatoyama S, Takata N, Hayashi K, et al
     Immune Checkpoint Inhibitor Therapy for Patients With Non-small Cell Lung Cancer Ineligible for Platinum Doublet Chemotherapy.
     Anticancer Res. 2024;44:1241-1245.
     PubMed     Abstract available
     
     
     
130. KINOSHITA H, Kinoshita S, Kamoda H, Hagiwara Y, et al
     Combined Auranofin and Celecoxib Suppresses the Local Progression and Pulmonary Metastases of Osteosarcoma In Vivo.
     Anticancer Res. 2024;44:1045-1049.
     PubMed     Abstract available
     
     
     
131. YOSHIDA C, Kadota K, Ibuki E, Ishikawa R, et al
     Siglec10 Expression on Tumor-associated Macrophages Is an Independent Prognostic Factor in Stage I Lung Adenocarcinoma.
     Anticancer Res. 2024;44:1289-1297.
     PubMed     Abstract available
     
     
     February 2024
132. NATSUME K, Ye J, Mukai Y, Yamakawa K, et al
     Discrepancies Between Morphological and Immunohistochemical Classifications Are Associated With Prognoses and Subtypes of Lung Cancer.
     Anticancer Res. 2024;44:711-722.
     PubMed     Abstract available
     
     
     
133. TRINH JQ, Xiong Y, Smith LM, Abughanimeh O, et al
     Durvalumab Outcomes in Stage III Non-small Cell Lung Cancer: A Single-institution Study.
     Anticancer Res. 2024;44:605-612.
     PubMed     Abstract available
     
     
     
134. KANASAKI H, Ozawa Y, Nakamura N, Nagasaki K, et al
     Upfront Multiplex Gene Test Helps Prolong Survival in Advanced Non-small Cell Lung Cancer.
     Anticancer Res. 2024;44:723-730.
     PubMed     Abstract available
     
     
     
135. KURIHARA S, Nakamura R, Yoneyama S, Takase S, et al
     Prognostic Impact of Preoperative Assessment of Muscle Mass and Strength in Surgically Resected Lung Cancer.
     Anticancer Res. 2024;44:767-779.
     PubMed     Abstract available
     
     
     
136. NAKAO M, Kinoshita R, Kuriyama M, Kiyotoshi H, et al
     Serum CYFRA 21-1 Level as a Prognostic Marker for Extensive Disease Small Cell Lung Cancer.
     Anticancer Res. 2024;44:845-851.
     PubMed     Abstract available
     
     
     
137. CHECK JH, Check DL, DO TP, Srivastava M, et al
     Significant Palliative Benefits Following Therapy With Mifepristone for Advanced Treatment Resistant Small Cell Lung Cancer.
     Anticancer Res. 2024;44:659-664.
     PubMed     Abstract available
     
     
     
138. MATSUMOTO T, Toya R, Shimohigashi Y, Yamaguchi K, et al
     Influence of Respiratory Motion on Dose Distribution in Gastric Mucosa-associated Lymphoid Tissue Lymphoma Radiotherapy.
     Anticancer Res. 2024;44:687-694.
     PubMed     Abstract available
     
     
     
139. BARUT Z, Akdeniz FT, Isbir T
     Investigation of Mirna-223-3p Expression in Non-small Cell Lung Cancers.
     Anticancer Res. 2024;44:585-591.
     PubMed     Abstract available
     
     
     
140. HONG JM, Jeong BK, Han D, Kim K, et al
     CCR10-mediated Enhancement of T Cell Trafficking for Improved Tumor Immunotherapy.
     Anticancer Res. 2024;44:521-532.
     PubMed     Abstract available
     
     
     January 2024
141. NIEDER C, Aanes SG, Dalhaug A, Haukland EC, et al
     Sex Differences in Presentation, Treatment, and Survival in Patients Receiving Palliative (Chemo)Radiotherapy for Non-Small Cell Lung Cancer.
     Anticancer Res. 2024;44:301-305.
     PubMed     Abstract available
     
     
     
142. CHEN PM, Huang YH, Chen HH, Chu PY, et al
     Catalase Expression Is an Independent Prognostic Marker in Lung Adenocarcinoma.
     Anticancer Res. 2024;44:287-300.
     PubMed     Abstract available
     
     
     
143. TATE MK, Hernandez M, Chang JY, Lin SH, et al
     Metformin in Conjunction With Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer: Long-term Results of a Prospective Phase II Clinical Trial.
     Anticancer Res. 2024;44:133-137.
     PubMed     Abstract available
     
     
     
144. MOSER SS, Apter L, Solomon J, Chodick G, et al
     Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib vs. Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data.
     Anticancer Res. 2024;44:257-265.
     PubMed     Abstract available
     
     
     December 2023
145. AGOLLI L, Eroglu Z, Nicosia L, Habermehl D, et al
     Dosimetric Parameters After VMAT Adaptive Radiotherapy in Patients With Locally Advanced NSCLC Undergoing 4DCT.
     Anticancer Res. 2023;43:5573-5582.
     PubMed     Abstract available
     
     
     
146. LEE HH, Hsieh CC, Chang CC, Liao WT, et al
     YTHDF3 Modulates EGFR/ATK/ERK/p21 Signaling Axis to Promote Cancer Progression and Osimertinib Resistance of Glioblastoma Cells.
     Anticancer Res. 2023;43:5485-5498.
     PubMed     Abstract available
     
     
     
147. KIMURA N, Kadota K, Ibuki E, Ishikawa R, et al
     (Pro)renin Receptor Down-regulation Is Associated With a Higher Risk of Recurrence in Lung Adenocarcinoma.
     Anticancer Res. 2023;43:5671-5680.
     PubMed     Abstract available
     
     
     
148. TONG X, Zhang R, Sun R, Yang W, et al
     Disclosing Potential Therapeutic Targets Associated With Osimertinib Resistance in the Non-small Cell Lung Cancer Cell Line H1975.
     Anticancer Res. 2023;43:5459-5474.
     PubMed     Abstract available
     
     
     
149. ENDO I, Amatya VJ, Kushitani K, Nakagiri T, et al
     Long Non-coding RNA LINC00152 Requires EZH2 to Promote Mesothelioma Cell Proliferation, Migration, and Invasion.
     Anticancer Res. 2023;43:5367-5376.
     PubMed     Abstract available
     
     
     
150. LIU B, Pu ZY, Wang L, Fang J, et al
     Inhibiting miR-33b-5p Enhances Chemoresistance in Lung Adenocarcinoma by Targeting YWHAH to Regulate Epithelial-mesenchymal Transition.
     Anticancer Res. 2023;43:5447-5458.
     PubMed     Abstract available
     
     
     
151. LIN HW, Shih TW, Amanna A, Chang MS, et al
     PHRF1 Promotes Cell Invasion by Modulating SOX4 Expression in Colorectal Cancer HCT116-p53(-/-) Cells.
     Anticancer Res. 2023;43:5437-5446.
     PubMed     Abstract available
     
     
     
152. ZHANG XW, Mohr J, Halama N, Koschny R, et al
     Analysis of an Unselected Patient Cohort With Advanced Colorectal Carcinoma from a Maximum Care Center.
     Anticancer Res. 2023;43:5589-5596.
     PubMed     Abstract available
     
     
     November 2023
153. ITO S, Tsurumi K, Shindo N, Soma S, et al
     Multi-gene Liquid Biopsy to Detect Resistance to First-line Osimertinib in Patients With EGFR-mutated Lung Adenocarcinoma.
     Anticancer Res. 2023;43:5031-5040.
     PubMed     Abstract available
     
     
     
154. SAKAI K, Kuramoto J, Takahashi T, Kawano Y, et al
     Impact of Locoregional Therapies for Brain Lesions on Survival in Patients With Non-small Cell Lung Cancer With Multiple Extrathoracic Metastases.
     Anticancer Res. 2023;43:5107-5114.
     PubMed     Abstract available
     
     
     
155. ITO A, Tarukawa T, Suzuki Y, Sakaguchi T, et al
     Clinicopathological and Molecular Characteristics Promoting PD-L1 Expression in Early-stage Lung Adenocarcinoma and Squamous Cell Carcinoma.
     Anticancer Res. 2023;43:5197-5204.
     PubMed     Abstract available
     
     
     
156. YANG T, Si Q, Liu M, DU R, et al
     Novel Biomarker miRNA-625-3p Promotes Cell Proliferation and Metastasis of Lung Adenocarcinoma by Targeting KLF9.
     Anticancer Res. 2023;43:4923-4935.
     PubMed     Abstract available
     
     
     
157. MATSUDO K, Takenaka T, Hashinokuchi A, Nagano T, et al
     Impact of Chronic Obstructive Pulmonary Disease on the Long-term Prognosis of Patients Undergoing Lobectomy for Non-small-cell Lung Cancer: A Propensity Score-matched Analysis.
     Anticancer Res. 2023;43:5215-5222.
     PubMed     Abstract available
     
     
     
158. ISOYAMA-SHIRAKAWA Y, Yoshitake T, Ninomiya K, Asai K, et al
     Combination of Clinical Factors and Radiomics Can Predict Local Recurrence and Metastasis After Stereotactic Body Radiotherapy for Non-small Cell Lung Cancer.
     Anticancer Res. 2023;43:5003-5013.
     PubMed     Abstract available
     
     
     October 2023
159. TAMURA T, Numata T, Yanai H, Nakamura R, et al
     Atezolizumab for EGFR-mutated Non-small Cell Lung Cancer Patients: An Observation Study in Ibaraki Group (ATTENTION-IBARAKI).
     Anticancer Res. 2023;43:4583-4591.
     PubMed     Abstract available
     
     
     
160. SAWABATA N, Morita K, Tatsumi S, Fujii T, et al
     A Novel Filtration Membrane for Clustered Circulating Tumor Cell Extraction: A Prospective Feasibility Study.
     Anticancer Res. 2023;43:4683-4690.
     PubMed     Abstract available
     
     
     
161. NAGAMINE H, Yashiro M, Yoshimoto N, Izumi M, et al
     RBM17 Expression Is Associated With the Efficacy of ICI Monotherapy in NSCLC With Low PD-L1 Expression.
     Anticancer Res. 2023;43:4663-4672.
     PubMed     Abstract available
     
     
     
162. ZHAO QI, Ren W, Gao S, Mu N, et al
     Immune Cell Infiltration and Clinical Significance of Angiogenesis-related Genes in Lung Adenocarcinoma.
     Anticancer Res. 2023;43:4473-4489.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum